Michiel Van der Heijden, MD, PhD, joined Tus to review bladder cancer presentations

from the 2023 ASCO GU Cancers Symposium, including the phase 1B NABUCCO trialon the use of high- or low-dose preoperative ipilimumab with nivolumab forstage III urothelial cancer, as well as his paper on the use of predictivebiomarkers for survival benefit with ramucirumab in the RANGE trial. Dr. Vander Heijden is a medical oncologist research group leader at The NetherlandsCancer Institute, focusing on the improvement of bladder cancer treatment.